The Evolving Narrative of HDL-C: Contemporary Insights on Quality vs. Quantity for Targeting Cardio Protection

Overview

The future of HDL as a biomarker for CVD is rapidly evolving, and new information regarding the structural and functional capacity of HDL is emerging. We invite you to attend this two-hour, CME-certified symposium that will feature three leading experts in the field of lipidology as they focus on addressing the HDL hypothesis, what we have learned from the past, and its potential for the future. Expert faculty will provide insights into clinical trials and what those clinical trials have taught us about HDL-C-elevating therapies as compared to trials focusing on HDL function for primary and secondary cardio prevention.

Provider Statement

CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support Statement

This activity is supported by educational funding provided by CSL Behring.

Target Audience

This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, with an interest in lipid management.

Learning Objectives

At the Conclusion of this activity, participants should be able to:

• Describe unmet needs in targeting HDL-C for ASCVD risk reduction
• Recognize clinical significance of HDL-C functional capacity for atheroprotection and ASCVD risk reduction
• Review the role of CEC in the reverse cholesterol transport (RCT) pathway of HDL-C to promote cardioprotection
• Discuss the latest clinical data for novel treatment strategies targeting functional aspects of HDL-C to reduce ASCVD risk.

Faculty

Program Chair
Christie M. Ballantyne, MD
Chief, Section of Cardiovascular Research
Director, Center for Cardiometabolic Disease Prevention
Professor of Medicine, Molecular and Human Genetics, and Integrative Physiology
Baylor College of Medicine
Houston, TX

Vera A. Bittner, MD, MSPH, MNLA
Endowed Scholar in Cardiovascular Disease Prevention
Section Head, General Cardiology, Prevention and Imaging
University of Alabama at Birmingham
Birmingham, AL

Robert S. Rosenson, MD, FNLA
Director of Metabolism and Lipids
Mount Sinai Health System
Professor of Medicine (Cardiology)
Icahn School of Medicine at Mount Sinai
New York, NY

Reviewer

Kathleen H. Byrne, CRNP, MS, FNLA
Lipid Specialist

Accreditation

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

Pharmacist Accreditation Statement
Universal Activity Number – JA0007192-0000-23-025-H01-P (Application)
This Activity has been approved for 1.0 contact hour(s) (.10CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
The maximum number of hours awarded for this CE activity is 1.0 contact hours. This continuing education activity offered 0.50 pharmacotherapy contact hours.

Credit Designation

CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

How to Participate in this Activity and Obtain CME Credit

Statements of credit will be awarded based on the participant's completion and submission of the activity evaluation form. A statement of credit will be available for download upon completion of the online evaluation form. To receive credit, participants should complete the online course, score at least 30% on the post-test, and submit the evaluation. The deadline to claim credit is July 11, 2024.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

IMPORTANT* Pharmacists MUST request credit before (60 days from the last day to claim credit). Credit requested after this date will be subject to a fee by the accreditation board.

Disclosures

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.  All disclosures have been reviewed and resolved at this time.

Faculty reports the following relationship(s)

Christie M. Ballantyne, MD, FNLA
Consultant- 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken*, Esperion, Genentech, Gilead, Illumina, Ionis, Matinas BioPharma Inc, Merck, New Amsterdam*, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic
Grant/Research Support- Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic

Vera A. Bittner, MD, MSPH, MNLA
Grant/Research Support- Amgen, Astra Zeneca, DalCor, Esperion, Novartis, Pfizer, Sanofi and Regeneron
Consultant- Pfizer, Verve Therapeutics

Robert S. Rosenson, MD, FNLA
Consultant- Amgen, Arrowhead, Eli Lilly, Lipigon, Novartis, Regeneron, Verve Therapeutics, CRISPR Therapeutics, Precision BioSciences, UltraGenix
Royalties- Wolters Kluwer
Stock Ownership- MediMergent, LLC

Reviewers report the following relationship(s)

NLA Staff reports no industry relationships.

Kathleen H. Byrne, CRNP, MS, FNLA reports no industry relationships.

Unlabeled and Investigational Usage

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Copyright Statement

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

CME Questions?

Questions about this CME activity may be sent to the National Lipid Association’s Continuing Medical Education Department at cme@lipid.org.